APVO
Aptevo Therapeutics Inc.Company Information
- Company Name
- Aptevo Therapeutics Inc.
- CIK
- CIK0001671584
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- APVO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- APVO
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-11-10
- Last sale
- —
- Shares purchased (TTM)
- 13,513
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 28,929
- Shares outstanding
- 1,196,364
- Ownership
- 2.42%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -40.82%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 10 | 15 | 22 | 21 | 9 | 2 | 9 | 8 | 8 | 10 | 17 | 19 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | - | - | - | 2 | - | - | - | - | - | ||||||
| Prepaid Expense Current | - | 1 | 1 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Current | - | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets Current | 11 | 16 | 23 | 23 | 11 | 4 | 11 | 10 | 10 | 12 | 19 | 21 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | ||||||
| Assets | 15 | 20 | 27 | 27 | 16 | 8 | 16 | 15 | 15 | 18 | 25 | 27 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Other Accrued Liabilities Current | - | - | - | 2 | 3 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | ||||||
| Accounts Payable Current | 1 | 1 | 1 | - | - | - | 1 | - | - | - | - | - | ||||||
| Accrued Liabilities And Other Liabilities | 3 | 3 | 4 | - | - | - | 4 | - | - | - | - | - | ||||||
| Employee Related Liabilities Current | - | 1 | 2 | 2 | 1 | 0 | 2 | 1 | 1 | 2 | 2 | 2 | ||||||
| Other Liabilities Current | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | - | 1 | 1 | 1 | - | - | - | - | - | ||||||
| Liabilities Current | 5 | 5 | 6 | 6 | 5 | 5 | 6 | 6 | 5 | 6 | 7 | 7 | ||||||
| Operating Lease Liability Noncurrent | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | ||||||
| Liabilities | 8 | 8 | 10 | 10 | 9 | 10 | 11 | 11 | 10 | 12 | 13 | 12 | ||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 294 | 293 | 292 | 286 | 267 | 252 | 252 | 246 | 241 | 236 | 236 | 232 | ||||||
| Retained Earnings Accumulated Deficit | -288 | -282 | -275 | -269 | -260 | -254 | -248 | -241 | -236 | -230 | -223 | -218 | ||||||
| Stockholders Equity | 6 | 12 | 17 | 17 | 7 | -1 | 5 | 4 | 4 | 6 | 12 | 15 | ||||||
| Liabilities And Stockholders Equity | 15 | 20 | 27 | 27 | 16 | 8 | 16 | 15 | 15 | 18 | 25 | 27 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 1 | 1 | 1 | 14 | 3 | 1 | 4 | 17 | 4 | 1 | 12 | 14 | ||||||
| Shares Outstanding | 1 | 1 | 1 | 14 | 3 | 1 | 4 | 17 | 4 | 1 | 12 | 14 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAptevo Therapeutics Inc. (APVO) — SEC Financial Statements & Analysis
Aptevo Therapeutics Inc. (APVO) is a pharmaceutical preparations company, incorporated in DE. Aptevo Therapeutics Inc. trades on Nasdaq as: APVO. Aptevo Therapeutics Inc. (APVO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Aptevo Therapeutics Inc. carries a market cap of $5.31M, a P/E ratio of -0.19x, a P/B ratio of 0.88x, an enterprise value of $-4.49M, and an EV/EBITDA multiple of 0.17x. On profitability, it posts a Return on Equity (ROE) of -446.89% and a Return on Assets (ROA) of -186.29%. Per share, it reports EPS of $-23.47, diluted EPS of $-23.47, free cash flow per share of $-21.18, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 16.86% year-over-year, and EPS growth of -95.99% year-over-year. On the balance sheet, it maintains a current ratio of 2.08x, a quick ratio of 1.89x, working capital of $5.61M, a debt-to-equity ratio of 1.40x, a debt ratio of 0.58, free cash flow of $-25.34M (TTM), and net debt of $-9.80M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.31M
- P/E TTM
- -0.19x
- EPS TTM
- $-23.47
- P/B TTM
- 0.88x
- ROE TTM
- -446.89%
- ROA TTM
- -186.29%
- Debt To Equity
- 1.40x
- Free Cash Flow TTM
- $-25.34M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aptevo Therapeutics Inc. in?
Aptevo Therapeutics Inc. (APVO) operates in the Pharmaceutical Preparations industry.
What exchange does APVO trade on?
Aptevo Therapeutics Inc. (APVO) trades on the Nasdaq.
Where is Aptevo Therapeutics Inc. incorporated?
Aptevo Therapeutics Inc. is incorporated in DE.
When was Aptevo Therapeutics Inc. (APVO)'s most recent SEC filing?
Aptevo Therapeutics Inc. (APVO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is APVO's market cap?
Aptevo Therapeutics Inc. (APVO) has a market capitalization of $5.31M as of 2026-06-30.
What is APVO's EPS (earnings per share)?
Aptevo Therapeutics Inc. (APVO)'s trailing twelve month EPS is $-23.47 as of 2026-06-30.
What is APVO's ROE (return on equity)?
Aptevo Therapeutics Inc. (APVO)'s trailing twelve month Return on Equity (ROE) is -446.89% as of 2026-06-30.
What is APVO's ROA (return on assets)?
Aptevo Therapeutics Inc. (APVO)'s trailing twelve month Return on Assets (ROA) is -186.29% as of 2026-06-30.
What is APVO's EV/EBITDA?
Aptevo Therapeutics Inc. (APVO)'s trailing twelve month EV/EBITDA is 0.17x as of 2026-06-30.